Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan reported Q1 2026 net loss of $49.7 million, or $0.75 per share, with cash and investments of $393.3 million providing runway into 2029. The FDA accepted the NDA for zipalertinib in relapsed EGFR ex20ins NSCLC, setting a PDUFA target action date of February 27, 2027, while partner Taiho completed enrollment in the pivotal REZILIENT3 study.
Key figures
- Net Loss
- 49700000
- Ga Expenses
- 11600000
- Rd Expenses
- 42100000
- Cash Position
- $393.3 million
- Runway
- into 2029
- Pdufa Date
- February 27, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.